[go: up one dir, main page]

DE69717647D1 - 3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen - Google Patents

3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen

Info

Publication number
DE69717647D1
DE69717647D1 DE69717647T DE69717647T DE69717647D1 DE 69717647 D1 DE69717647 D1 DE 69717647D1 DE 69717647 T DE69717647 T DE 69717647T DE 69717647 T DE69717647 T DE 69717647T DE 69717647 D1 DE69717647 D1 DE 69717647D1
Authority
DE
Germany
Prior art keywords
mercaptoacetylamino
metalloproteinases
oxo
inhibitors
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69717647T
Other languages
English (en)
Other versions
DE69717647T2 (de
Inventor
M Warshawsky
A Flynn
V Patel
W Beight
P Burkhart
Jiu-Tsair Tsay
J Janusz
Jian Shen
M Dharanipragada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69717647D1 publication Critical patent/DE69717647D1/de
Publication of DE69717647T2 publication Critical patent/DE69717647T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69717647T 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen Expired - Lifetime DE69717647T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71929196A 1996-09-19 1996-09-19
PCT/US1997/013738 WO1998012211A1 (en) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Publications (2)

Publication Number Publication Date
DE69717647D1 true DE69717647D1 (de) 2003-01-16
DE69717647T2 DE69717647T2 (de) 2003-09-25

Family

ID=24889504

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69717647T Expired - Lifetime DE69717647T2 (de) 1996-09-19 1997-08-04 3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen

Country Status (20)

Country Link
EP (1) EP0928291B1 (de)
JP (1) JP3962091B2 (de)
KR (1) KR100545460B1 (de)
CN (1) CN1150205C (de)
AR (1) AR009363A1 (de)
AT (1) ATE229034T1 (de)
AU (1) AU718055B2 (de)
BR (1) BR9713207A (de)
CA (1) CA2266759C (de)
DE (1) DE69717647T2 (de)
DK (1) DK0928291T3 (de)
ES (1) ES2184126T3 (de)
HU (1) HUP9904165A3 (de)
IL (2) IL129035A0 (de)
NO (1) NO991316L (de)
NZ (1) NZ334490A (de)
PT (1) PT928291E (de)
TW (1) TW445262B (de)
WO (1) WO1998012211A1 (de)
ZA (1) ZA978307B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040553A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metallo-proteinases
WO2000040577A1 (en) * 1998-12-31 2000-07-13 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6486193B2 (en) 1998-12-31 2002-11-26 Aventis Pharmaceuticals Inc. 3-substituted pyrrolidines useful as inhibitors of matrix metalloproteinases
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
EP1156803A4 (de) 1999-02-09 2004-03-17 Bristol Myers Squibb Co LACTAM INHIBITOREN DES FXa UND METHODE
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
US7141607B1 (en) 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
OA12323A (en) 2000-03-21 2006-05-15 Smithkline Beecham Corp Protease inhibitors.
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7704521B2 (en) 2007-04-11 2010-04-27 Zinpro Corporation Rumen protected essential amino acids
US20080255234A1 (en) * 2007-04-11 2008-10-16 Zinpro Corporation Rumen protected lysine
US11091751B2 (en) 2017-05-31 2021-08-17 BRAIN Biotech AG Optimization of the expression of serine proteases in host cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE106087T1 (de) * 1987-03-17 1994-06-15 Res Corp Technologies Inc Synthetische inhibitoren von säugetier- collagenase.
JPH07304746A (ja) * 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピンカルボン酸誘導体
DK0784629T3 (da) * 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
CN1150205C (zh) 2004-05-19
DK0928291T3 (da) 2003-03-17
IL129035A0 (en) 2000-02-17
CN1234039A (zh) 1999-11-03
IL129035A (en) 2006-12-10
JP3962091B2 (ja) 2007-08-22
CA2266759C (en) 2004-10-26
AU3827897A (en) 1998-04-14
KR20000036246A (ko) 2000-06-26
ATE229034T1 (de) 2002-12-15
NZ334490A (en) 2000-08-25
AR009363A1 (es) 2000-04-12
AU718055B2 (en) 2000-04-06
ZA978307B (en) 1998-03-19
TW445262B (en) 2001-07-11
HUP9904165A3 (en) 2002-01-28
HK1020741A1 (en) 2000-05-19
DE69717647T2 (de) 2003-09-25
NO991316D0 (no) 1999-03-18
BR9713207A (pt) 2000-04-04
KR100545460B1 (ko) 2006-01-24
JP2001501926A (ja) 2001-02-13
ES2184126T3 (es) 2003-04-01
NO991316L (no) 1999-05-18
EP0928291A1 (de) 1999-07-14
CA2266759A1 (en) 1998-03-26
WO1998012211A1 (en) 1998-03-26
EP0928291B1 (de) 2002-12-04
PT928291E (pt) 2003-03-31
HUP9904165A2 (hu) 2000-03-28

Similar Documents

Publication Publication Date Title
DE59913617D1 (de) Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
DE60030574D1 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
DE69734149D1 (de) Cinoline derivate und verwendung als heilmittel
DE69736994D1 (de) Ionische Malonsäuredinitril Derivate und deren Verwendung
DE69407561D1 (de) Harnstoff Derivate und deren Verwendung als ACAT Inhibitoren
DE69629721D1 (de) Carnamoyloxy derivate von mutilin und deren verwendung als antibakterielles mittels
ATE277895T1 (de) 4-brom or 4-iod-phenylamino- benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
DE60133897D1 (de) Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
DE69332898D1 (de) 4-Carboxamidopiperidinderivate und ihre Verwendung als Neurokinin Antagonisten
DE69622148D1 (de) Chinazozin derivate und deren verwendung
DE69833223D1 (de) 4-aminothiazol derivate, deren herstellung und deren verwendung als inhibitoren cyclin-abhängiger kinasen
DE69720194D1 (de) Piperazinonphenyloxazolidinon derivate und ihre verwendung als antibakterielle mittel
ATE268761T1 (de) Substituierte quinazolin-derivate und ihre verwendung als tyrosin-kinase inhibitoren
DE59908600D1 (de) Substituierte benzimidazole und ihre verwendung als parp inhibitoren
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE69529849D1 (de) Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
DE59711847D1 (de) Substituierte aza- und diazacycloheptan- und -cyclooctanverbindungen und deren verwendung
DE69717647D1 (de) 3-mercaptoacetylamino-1,5-substituierte-2-oxo-azepan derivate und deren verwendung als inhibitoren von matrix-metalloproteinasen
DE69818248D1 (de) Chinolin- und chinazolin-derivate als crf antagonisten
DE69826693D1 (de) Amidinoderivate und ihre verwendung als thrombininhibitoren
DE69718791D1 (de) Neuartige aminosäurederivate und deren verwendung als thrombininhibitoren
DE3774858D1 (de) Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
ATE196294T1 (de) Piperazin-derivate und ihre verwendung als 5-ht1a-antagoniste
DE69703437D1 (de) 2-(3h)-oxazolone-derivate und ihre verwendung als cox-2 inhibitoren
DE69510228D1 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DEL., US

8327 Change in the person/name/address of the patent owner

Owner name: AVENTISUB II INC., GREENVILLE, DEL., US